Hepatitis E Diagnostic Tests Market Expected to Reach $93.5 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Hepatitis E Diagnostic Tests Market," The hepatitis e diagnostic tests market size was valued at $61.69 million in 2021, and is estimated to reach $93.5 million by 2031, growing at a CAGR of 4.2% from 2022 to 2031. 

Hepatitis E diagnostic test market mainly involves the sales and distribution of hepatitis E diagnostic tests kits by the key market players. Hepatitis E is the infection caused by hepatitis E virus (hepevirus), which is an inflammation caused to the liver. This infection includes symptoms such nausea and jaundice which further leads to acute hepatitis in normal people and chronic hepatitis in immunosuppressed people. Furthermore, if chronic hepatitis remains undiagnosed and untreated it may lead to severe conditions such as cirrhosis and liver cancer.

World Health Organization states that around 30% (15–45%) of infected people clear the infection within 6 months of occurrence without any treatment. The remaining 70% of people may develop chronic infection, having the risk of cirrhosis ranging from 15% to 30% within 20 years. Thus, the need for early diagnosis and treatment of the condition is necessary, which further rises the demand for hepatitis E diagnostic test kits, and propels the hepatitis E diagnostic tests market growth.In addition, factors that drive the growth of the global hepatitis E diagnostic tests market trends include high prevalence of hepatitis E cases, rise in awareness about risk factors associated with hepatitis E if remained untreated, advancements in the field of diagnosis and treatment, and rise in investments by the public and private players in the R&D activities in this field.Moreover, the new product launches and product approvals by the public and private players is anticipated to provide a lucrative opportunity for the market. For instance, in August 2022, Roche announced the launch of a digital PCR system, which is a powerful new diagnostics platform in the fight against cancer and other infectious diseases. The new system has the potential to find and quantify rare and hard to detect mutations allowing for early diagnosis of severe hepatitis infections.

In addition, the government and non-government organizations in the developed as well as developing countries focus on creating awareness among the population about hepatitis diseases and related risk factors. Various campaigns and drives are arranged by different organizations which further creates awareness among the population about the causes and symptoms about the infection. It is necessary to create awareness among people about the safety of drinking water, and various methods to stop this spread of infection from drinking water, as hepatitis infection is caused due to drinking water contaminated by feces. In addition, the government have also taken initiatives to spread knowledge and information about the advanced diagnostic techniques which will help in early detection and treatment of the infection and avoid any serious conditions associated with it. This, further expand the market of hepatitis E diagnostic tests.

The hepatitis E diagnostic tests industry is segmented on the basis of test type, end user, and region. On the basis of test type, the market is segmented into HEV IgM ELISA Test, HEV IgG ELISA Test, and RT-PCR test. The HEV IgM ELISA Test segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the rise in advancements in this segment which offers accurate and immediate results in diagnosis of infectious diseases.On the basis of end user, the market is categorized into hospitals, diagnostic centers and others (research centers, blood bank, point of care, standalone laboratories). In 2021, the diagnostic centers segment held the largest Hepatitis E Diagnostic tests market share of the global hepatitis E diagnostic tests market, and is expected to grow at the highest CAGR during the forecast period. Increase in patient visits to the diagnostic centers after the COVID-19 pandemic as they offer the precise testing and thus assist the healthcare provider to decide the treatment regime.

Asia-Pacific acquired the major share of the hepatitis E diagnostic tests market in 2021, is expected to register highest CAGR from 2022 to 2031, owing to the rapid changes in the environmental conditions and associated viral and bacterial infections which leads to severe viral endemics in this region.

Key findings of the study

• By test type, the HEV IgM ELISA Test segment was the highest contributor to the market in 2021.
• By end user, the diagnostic centers segment held the highest position in terms of revenue in 2021, and are expected to grow at the highest CAGR during the forecast period
• Region wise, Asia-Pacific garnered the largest revenue share in 2021, and is anticipated to grow at the highest CAGR during the forecast period.